Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Beer

Showing results (751-760 of 888) with videos related to

Pageof 89
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancerA J Armstrong, P Lin, C S Higano, et al.
Urologic Oncology|August 6, 2011
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancerJianqing Lin, Marianna Zahurak, Tomasz M Beer, et al.
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 2, 2014
Intermediate length C9orf72 expansion in an ALS patient without classical C9orf72 neuropathologyAlexander M Beer, Johnathan Cooper-Knock, Adrian Higginbottom, et al.
BJU International|September 8, 2006
The medical management of prostate cancer: a multidisciplinary team approachCora N Sternberg, Michael Krainer, William K Oh, et al.
Gynecologic Oncology|April 9, 2020
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effectRebecca C Arend, Hannah M Beer, Yael C Cohen, et al.
Oncotarget|July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancerJulie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2003
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancerRandall P Rago, Albert Einstein, Richard Lush, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Prostate cancer-associated gene expression alterations determined from needle biopsiesDavid Z Qian, Chung-Ying Huang, Catherine A O'Brien, et al.
Pageof 89

Showing results (751-760 of 888) with videos related to

Sort By:
Pageof 89
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancerA J Armstrong, P Lin, C S Higano, et al.
Urologic Oncology|August 6, 2011
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancerJianqing Lin, Marianna Zahurak, Tomasz M Beer, et al.
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 2, 2014
Intermediate length C9orf72 expansion in an ALS patient without classical C9orf72 neuropathologyAlexander M Beer, Johnathan Cooper-Knock, Adrian Higginbottom, et al.
BJU International|September 8, 2006
The medical management of prostate cancer: a multidisciplinary team approachCora N Sternberg, Michael Krainer, William K Oh, et al.
Gynecologic Oncology|April 9, 2020
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effectRebecca C Arend, Hannah M Beer, Yael C Cohen, et al.
Oncotarget|July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancerJulie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2003
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancerRandall P Rago, Albert Einstein, Richard Lush, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Prostate cancer-associated gene expression alterations determined from needle biopsiesDavid Z Qian, Chung-Ying Huang, Catherine A O'Brien, et al.
Pageof 89